Abstract
To better understand how heparin structure affects its activity the relationships between the functional domains for inhibitor binding and charge density were investigated to determine how these domains affect heparin-mediated thrombin inhibition by two different heparin-dependent protease inhibitors, antithrombin (AT) and heparin cofactor II (HC II). A series of heparins, fractionated systematically by charge density, was further fractionated on antithrombin agarose to isolate more homogeneous subfractions that were either inactive or highly active with respect to thrombin inhibition by AT. With AT, the activities of the AT-active subfractions increased sharply with heparin charge density, while those with little or no affinity for AT were virtually inactive. In contrast, with HC II inhibitor, the activities of the heparins depended only upon their charge densities and were independent of AT affinity. At any given charge density, the heparin before fractionation by AT affinity and the fractions that were highly active and inactive with AT were all equally active with HC II. The two inhibitors also differed in their reactivity with heparan sulfate and dermatan sulfate. A charge-density effect with the subfractions having similar high affinity for AT demonstrates that charge density represents a heparin functional domain that is independent of the AT-binding domain. The behavior of the AT-inactive heparins, being fully active with HC II, demonstrates the functional domain necessary for AT binding is not needed to produce HC II activity.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Danielsson A., Björk I. Binding to antithrombin of heparin fractions with different molecular weights. Biochem J. 1981 Feb 1;193(2):427–433. doi: 10.1042/bj1930427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Griffith M. J. Kinetic analysis of the heparin-enhanced antithrombin III/thrombin reaction. Reaction rate enhancement by heparin-thrombin association. J Biol Chem. 1979 Dec 10;254(23):12044–12049. [PubMed] [Google Scholar]
- Griffith M. J., Marbet G. A. Dermatan sulfate and heparin can be fractionated by affinity for heparin cofactor II. Biochem Biophys Res Commun. 1983 Apr 29;112(2):663–670. doi: 10.1016/0006-291x(83)91514-0. [DOI] [PubMed] [Google Scholar]
- Holmer E., Söderström G., Andersson L. O. Properties of antithrombin III depleted plasma. I. Effect of heparin. Thromb Res. 1980 Jan 1;17(1-2):113–124. doi: 10.1016/0049-3848(80)90299-6. [DOI] [PubMed] [Google Scholar]
- Hurst R. E., Menter J. M., West S. S., Settine J. M., Coyne E. H. Structural basis for the anticoagulant activity of heparin. 1. Relationship to the number of charged groups. Biochemistry. 1979 Oct 2;18(20):4283–4287. doi: 10.1021/bi00587a004. [DOI] [PubMed] [Google Scholar]
- Hurst R. E., Settine J. M., Poon M. C., Lurie A. Heterogeneity in the composition of commercial heparins: comparison of anticoagulant activities and biochemical compositions of anionic density-fractionated heparins. Thromb Res. 1982 Feb 1;25(3):255–265. doi: 10.1016/0049-3848(82)90245-6. [DOI] [PubMed] [Google Scholar]
- Hurst R. E., van Dedem G., Settine J. M. Biophysical characteristics of anionic density-fractionated mucosal heparins in relation to potencies in anticoagulant and thrombin-inhibition assays. Thromb Res. 1981 Jun 1;22(5-6):633–643. doi: 10.1016/0049-3848(81)90061-x. [DOI] [PubMed] [Google Scholar]
- Hök M., Björk I., Hopwood J., Lindahl U. Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett. 1976 Jul 1;66(1):90–93. doi: 10.1016/0014-5793(76)80592-3. [DOI] [PubMed] [Google Scholar]
- Kindness G., Long W. F., Williamson F. B. The anticoagulant activity of dermatan sulphates: evidence against the involvement of antithrombin III. Br J Pharmacol. 1981 Jan;72(1):81–88. doi: 10.1111/j.1476-5381.1981.tb09108.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lam L. H., Silbert J. E., Rosenberg R. D. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun. 1976 Mar 22;69(2):570–577. doi: 10.1016/0006-291x(76)90558-1. [DOI] [PubMed] [Google Scholar]
- Laurent T. C., Tengblad A., Thunberg L., Hök M., Lindahl U. The molecular-weight-dependence of the anti-coagulant activity of heparin. Biochem J. 1978 Nov 1;175(2):691–701. doi: 10.1042/bj1750691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lindahl U., Bäckström G., Thunberg L., Leder I. G. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6551–6555. doi: 10.1073/pnas.77.11.6551. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lundblad R. L., Kingdon H. S., Mann K. G. Thrombin. Methods Enzymol. 1976;45:156–176. doi: 10.1016/s0076-6879(76)45017-6. [DOI] [PubMed] [Google Scholar]
- Menter J. M., Hurst R. E., Corliss D. A., West S. S., Abrahamson E. W. Structural basis for the anticoagulant activity of heparin. 2. Relationship of anticoagulant activity to the thermodynamics and fluorescence fading kinetics of acridine orange-heparin complexes. Biochemistry. 1979 Oct 2;18(20):4288–4292. doi: 10.1021/bi00587a005. [DOI] [PubMed] [Google Scholar]
- Oosta G. M., Gardner W. T., Beeler D. L., Rosenberg R. D. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A. 1981 Feb;78(2):829–833. doi: 10.1073/pnas.78.2.829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tollefsen D. M., Majerus D. W., Blank M. K. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem. 1982 Mar 10;257(5):2162–2169. [PubMed] [Google Scholar]